Alder BioPharmaceuticals Inc. (ALDR) and GTx Inc. (NASDAQ:GTXI) Comparison side by side

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and GTx Inc. (NASDAQ:GTXI), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alder BioPharmaceuticals Inc. 12 0.00 N/A -4.78 0.00
GTx Inc. 1 0.00 N/A -1.67 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 has Alder BioPharmaceuticals Inc. and GTx Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Alder BioPharmaceuticals Inc. 0.00% -193.2% -67.2%
GTx Inc. 0.00% 0% 0%

Risk & Volatility

Alder BioPharmaceuticals Inc. is 179.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 2.79. GTx Inc.’s 2.43 beta is the reason why it is 143.00% more volatile than Standard & Poor’s 500.

Analyst Recommendations

Recommendations and Ratings for Alder BioPharmaceuticals Inc. and GTx Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alder BioPharmaceuticals Inc. 0 2 4 2.67
GTx Inc. 0 0 0 0.00

Alder BioPharmaceuticals Inc.’s upside potential currently stands at 80.68% and an $20.67 average target price.

Insider and Institutional Ownership

The shares of both Alder BioPharmaceuticals Inc. and GTx Inc. are owned by institutional investors at 0% and 28.2% respectively. 0.4% are Alder BioPharmaceuticals Inc.’s share held by insiders. Competitively, GTx Inc. has 17.7% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alder BioPharmaceuticals Inc. -8.6% -15.44% -21.34% -21.11% -27.72% 6.83%
GTx Inc. -10.34% -12.61% 6.34% -32.9% -94.03% 33.33%

For the past year Alder BioPharmaceuticals Inc. was less bullish than GTx Inc.


GTx Inc. beats Alder BioPharmaceuticals Inc. on 5 of the 7 factors.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The companyÂ’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.